Genetic background affects susceptibility to mammary hyperplasias and carcinomas in ApcMin/+ mice

Cancer Research

Volumn 61, Issue 8, 2001, Pages 3480-3485

  Moser, Amy Rapaich ^a   Hegge, Laura F ^a   Cardiff, Robert D ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYLNITROSOUREA;

ALLELISM; ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER SUSCEPTIBILITY; COLON POLYPOSIS; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC SUSCEPTIBILITY; INTESTINE TUMOR; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ALLELES; ANIMALS; CROSSES, GENETIC; FEMALE; GENES, APC; GENETIC PREDISPOSITION TO DISEASE; HYPERPLASIA; INTESTINAL NEOPLASMS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 0035870247     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. Population-based case-control studies of ovarian cancer
2. BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2
3. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat
4. Genetic identification of multiple loci that control breast cancer susceptibility in the rat
5. Spontaneous lesions in aging FVB/N mice
6. FVB/N: An inbred mouse strain preferable for transgenic analyses
7. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias
8. Intestinal and extra-intestinal tumor multiplicities in the Apc1638N mouse model after exposure to X-rays
9. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
10. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse
11. Suppression of intestinal neoplasia by DNA hypomethylation
12. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase Matrilysin
13. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice
14. The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting
15. The Min (multiple intestinal neoplasia) mutation: Its effect on gut epithelial cell differentiation and interaction with a modifier system
16. The genetic background modifies the spontaneous and X-ray-induced tumor spectrum in the Apc1638N mouse model
17. Evolution in inbred strains of mice appears rapid
18. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia
19. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis
20. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice
21. Genealogy of the 129 inbred strains: 129/SvJ is a contaminated inbred strain
22. Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice
23. Genetic modulation of neu protooncogene-induced mammary tumorigenesis
24. In wap-ras transgenic mice, tumor phenotype but not cyclophosphamide-sensitivity is affected by genetic background
25. FVB/N mice: An inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin
26. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice
27. Morphology of mammary tumors in mice
28. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice
29. Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes
30. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of β-catenin
31. The oncogenic activation of β-catenin
32. β-Catenin is a target for the ubiquitin-proteasome pathway
33. Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK3β
34. WNT-1 and HGF regulate GSK3 β activity and β-catenin signaling in mammary epithelial cells
35. WNT targets. Repression and activation
36. Identification of c-MYC as a target of the APC pathway
37. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
38. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer
39. Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers
40. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein
41. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer
42. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients
43. Tissue reconstitution models of breast cancer
44. Lymphoid enhancer factor 1 directs hair follicle patterning and epithelial cell fate
45. De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated β-catenin in skin